Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
324 The University of Texas Rio Grande Valley (142212)
Principal Investigator: Biguetti,Claudia Cristina
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 125,719
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 9/1/22 - 8/31/27
Restricted Research: YES
Academic Discipline: School of Podiatric Medicine
Department, Center, School, or Institute: School of Podiatric Medicine
Title of Contract, Award, or Gift: Multifunctional Ionic Liquid Application for Treatment of Peri-implant Diseases
Name of Granting or Contracting Agency/Entity:
University of Texas at Dallas
CFDA Link: HHS
93.121
Program Title:
Oral Diseases and Disorders Research
CFDA Linked: Oral Diseases and Disorders Research
Note:
SAMs 1.1.1--Our research group has developed novel dicationic imidazolium-based ionic liquids (IonLs) with amino acidbased anionic moieties with multifunctionality for biomedical applications 13–16. We have demonstrated that IonL- coated Ti achieved a higher success rate of 78%with >60% bone-to-implant contact (BIC) versus uncoated Ti (67% success) in rat models. When compared to uncoated Ti, IonL-Ti implants also induced differential upregulation of several immunological genes, including inflammation resolution gene IL-10, in addition to bone matrix marker Spp115. Interestingly, these same target levels were significantly reduced in PI lesions relative to healthy samples in humans17. These findings motivated evaluation of the immunomodulatory impact of IonL coatings towards Ti-tissue re-integration, which we propose to study as a potential functionality for PI disease treatment. Our IonL coating can be used in combination with conventional decontamination protocols to remedy dysbiosis and bacterial overgrowth in the PI pocket, protect the implant surface during reintegration, and cue the host immune response to resolve inflammation and re-integrate with host tissue. Thus, this study will address the current clinical gap in treatment of PI diseases by elucidating the ability of IonL to (i) protect the implant surface during the acute healing phase, (ii) mitigate regrowth of bacterial biofilm, and (iii) actively modulate the immune response towards soft tissue healing and re-osseointegration.
Discussion: No discussion notes